Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. The company has a portfolio that includes five therapeutic programs either in clinical trials or preclinical studies. Viking’s lead clinical program, SARM Therapy, is being developed for the treatment of patients recovering from non-elective hip fracture surgery. It is currently entering phase II of trials and has shown results of improving lean body mass in the first 21 days following surgery. For more information, visit the company’s website at www.vikingtherapeutics.com.